SIGA TECHNOLOGIES INC

Listed Company

SIGACIK 0001010086NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$94.57M

Net Income

$23.28M

Total Assets

$219.47M

Equity

$198.82M

Shares Out

71.64M

Op. Cash Flow

$43.47M

Business

SIGA TECHNOLOGIES INC is a commercial-stage pharmaceutical company focused on developing, procuring and supplying medical countermeasures for orthopoxvirus diseases and related health security needs. The company’s principal product is TPOXX® (tecovirimat), available in oral and intravenous formulations for treatment of smallpox and related orthopoxvirus indications, and it supports clinical trials and regulatory activities. SIGA’s operations include contract manufacturing relationships, government procurement and research agreements, and post‑marketing activities. Products are sold primarily to the U.S. Government, foreign governments, government‑affiliated entities and through distributors for international markets.

Summary from filing dated 2025-03-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
RevenueFromContractWithCustomerExcludingAssessedTax	95	139	140	111	134
CostOfGoodsAndServicesSold	30	31	18	10	17
SellingGeneralAndAdministrativeExpense	21	25	22	35	18
ResearchAndDevelopmentExpense	20	12	16	23	10
CostsAndExpenses	71	69	56	68	45
OperatingIncomeLoss	24	70	84	43	89
NonoperatingIncomeExpense	7	6	4	1	101,172
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	30	76	88	44	89
IncomeTaxExpenseBenefit	−7	−17	−20	−10	−20
NetIncomeLoss	23	59	68	34	69
EarningsPerShareBasic	0.33	0.83	0.95	0.46	0.92
EarningsPerShareDiluted	0.32	0.82	0.95	0.46	0.91
WeightedAverageNumberOfSharesOutstandingBasic	72	71	71	73	75
WeightedAverageNumberOfDilutedSharesOutstanding	72	72	72	74	76

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
CashAndCashEquivalentsAtCarryingValue	155	155	150	99	103
AccountsReceivableNetCurrent	3	21	21	45	84
InventoryNet	49	50	64	39	20
PrepaidExpenseAndOtherAssetsCurrent	6	5	3	2	2
AssetsCurrent	213	231	239	186	209
PropertyPlantAndEquipmentNet	1	1	1	2	2
DeferredIncomeTaxAssetsNet	4	11	11	6	2
Goodwill	898,334	898,334	898,334	898,334	898,334
OtherAssetsNoncurrent	192,893	240,683	2	252,546	286,585
Assets	219	244	254	195	215
AccountsPayableCurrent	824,522	1	1	3	2
AccruedLiabilitiesCurrent	7	6	10	6	9
ContractWithCustomerLiabilityCurrent	10	10	21	11	—
AccruedIncomeTaxesCurrent	408,000	8	22	1	19
LiabilitiesCurrent	18	25	54	22	30
OtherLiabilitiesNoncurrent	3	3	—	—	—
Liabilities	21	29	57	25	40
CommitmentsAndContingencies	—	—	—	—	—
CommonStockValue	7,161	7,140	7,109	7,268	7,354
AdditionalPaidInCapitalCommonStock	242	239	236	234	226
RetainedEarningsAccumulatedDeficit	−43	−23	−39	−64	−52
StockholdersEquity	199	216	197	170	174
LiabilitiesAndStockholdersEquity	219	244	254	195	215

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
DepreciationDepletionAndAmortization	600,000	500,000	500,000	500,000	500,000
ShareBasedCompensation	4	4	2	2	1
InventoryWriteDownNetOfCredits	1	327,373	579,239	201,472	618,771
DeferredIncomeTaxExpenseBenefit	6	193,416	−5	−4	121,446
IncreaseDecreaseInDeferredRevenue	−90,800	−10	10	7	0
IncreaseDecreaseInAccountsReceivable	18	−35,178	24	38	−80
IncreaseDecreaseInInventories	−846,312	15	−26	−20	136,369
IncreaseDecreaseInPrepaidExpense	−609,437	−591,303	−3	171,811	48,963
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	−578,641	−6	2	2	1
IncreaseDecreaseInAccruedIncomeTaxesPayable	−8	−14	20	−18	18
NetCashProvidedByUsedInOperatingActivities	43	49	95	42	11
PaymentsForCapitalImprovements	−355,009	−42,450	−21,686	0	−50,620
NetCashProvidedByUsedInInvestingActivities	−355,009	−42,450	−21,686	0	−50,620
PaymentsRelatedToTaxWithholdingForShareBasedCompensation	−433,763	−799,895	−214,794	−12,533	−173,918
PaymentsForRepurchaseOfCommonStock	0	0	−11	−13	−26
PaymentsOfDividends	−43	−43	−32	−33	0
NetCashProvidedByUsedInFinancingActivities	−44	−43	−43	−46	−26
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	−433,848	5	51	−4	−15
NoncashLeaseRightofuseAssetsAndLiabilitiesAssumedNetOfDeferredRentExpense	0	462,686	0	0	733,715
StockIssued1	0	417,000	0	0	0
StockIssuedUponCashlessExercise	0	0	87,540	0	—
IncomeTaxesPaidRefund	8	30	4	31	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro